Literature DB >> 27189922

Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis.

Logan Banadyga1, Michael A Dolan2, Hideki Ebihara3.   

Abstract

Ebola, Marburg, and Ravn viruses, all filoviruses, are the causative agents of severe hemorrhagic fever. Much of what we understand about the pathogenesis of filovirus disease is derived from work with animal models, including nonhuman primates, which are considered the "gold standard" filovirus model since they faithfully recapitulate the clinical hallmarks of filovirus disease. However, rodent models, including the mouse, guinea pig, and hamster, also exist for Ebola, Marburg, and Ravn viruses, and although they may not reproduce all the clinical signs of filovirus disease, thanks to their relative ease of use and low cost, they are often the first choice for initial descriptions of virus pathogenesis and evaluation of antiviral prophylactics and therapeutics. Since filoviruses do not cause significant disease in adult, immunocompetent rodents, these models rely on "rodent-adapted" viruses that have been passaged several times through their host until virulence and lethality are achieved. In the process of adaptation, the viruses acquire numerous nucleotide/amino acid mutations that contribute to virulence in their rodent host. Interestingly, virus protein 24 (VP24) and nucleoprotein (NP) appear to be major virulence factors for ebolaviruses in rodents, whereas VP40 appears to be the major virulence factor for marburgviruses. By characterizing these mutations and understanding the molecular mechanisms that lead to the acquisition of virulence, we can gain better insight into the pathogenic processes that underlie filovirus disease in humans. These processes, and the viral and/or cellular proteins that contribute to them, will make attractive targets for the development of novel therapeutics and counter-measures. Published by Elsevier Ltd.

Entities:  

Keywords:  Ebola virus; Filovirus; Marburg virus; pathogenesis; rodent adaptation

Mesh:

Year:  2016        PMID: 27189922      PMCID: PMC5010511          DOI: 10.1016/j.jmb.2016.05.008

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  131 in total

1.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

2.  Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography.

Authors:  Tanmay A M Bharat; Takeshi Noda; James D Riches; Verena Kraehling; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka; John A G Briggs
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

3.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

4.  Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression.

Authors:  Shun-Ichiro Oda; Takeshi Noda; Kaveesha J Wijesinghe; Peter Halfmann; Zachary A Bornholdt; Dafna M Abelson; Tammy Armbrust; Robert V Stahelin; Yoshihiro Kawaoka; Erica Ollmann Saphire
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

5.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  [On the etiology of an unknown human infection originating from monkeys].

Authors:  R Siegert; H L Shu; W Slenczka; D Peters; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1967-12-22       Impact factor: 0.628

7.  Amino Acid Residue at Position 79 of Marburg Virus VP40 Confers Interferon Antagonism in Mouse Cells.

Authors:  Alicia R Feagins; Christopher F Basler
Journal:  J Infect Dis       Date:  2015-04-29       Impact factor: 5.226

8.  Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis.

Authors:  E Ryabchikova; L Kolesnikova; M Smolina; V Tkachev; L Pereboeva; S Baranova; A Grazhdantseva; Y Rassadkin
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection.

Authors:  Verena Krähling; Olga Dolnik; Larissa Kolesnikova; Jonas Schmidt-Chanasit; Ingo Jordan; Volker Sandig; Stephan Günther; Stephan Becker
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24

10.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

View more
  19 in total

Review 1.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

2.  Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.

Authors:  Philipp A Ilinykh; Jessica Graber; Natalia A Kuzmina; Kai Huang; Thomas G Ksiazek; James E Crowe; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 3.  A Forgotten Episode of Marburg Virus Disease: Belgrade, Yugoslavia, 1967.

Authors:  Elizabeta S Ristanović; Nenad S Kokoškov; Ian Crozier; Jens H Kuhn; Ana S Gligić
Journal:  Microbiol Mol Biol Rev       Date:  2020-05-13       Impact factor: 11.056

Review 4.  Immunobiology of Ebola and Lassa virus infections.

Authors:  Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best
Journal:  Nat Rev Immunol       Date:  2017-01-23       Impact factor: 53.106

5.  The Common Marmoset-Biomedical Research Animal Model Applications and Common Spontaneous Diseases.

Authors:  Hyo-Jeong Han; Sarah J Powers; Kathleen L Gabrielson
Journal:  Toxicol Pathol       Date:  2022-05-10       Impact factor: 1.930

6.  Evaluation of Ebola Virus Countermeasures in Guinea Pigs.

Authors:  Andrea Marzi
Journal:  Methods Mol Biol       Date:  2017

7.  Recently Identified Mutations in the Ebola Virus-Makona Genome Do Not Alter Pathogenicity in Animal Models.

Authors:  Andrea Marzi; Spencer Chadinah; Elaine Haddock; Friederike Feldmann; Nicolette Arndt; Cynthia Martellaro; Dana P Scott; Patrick W Hanley; Tolbert G Nyenswah; Samba Sow; Moses Massaquoi; Heinz Feldmann
Journal:  Cell Rep       Date:  2018-05-08       Impact factor: 9.423

Review 8.  Therapeutic strategies to target the Ebola virus life cycle.

Authors:  Thomas Hoenen; Allison Groseth; Heinz Feldmann
Journal:  Nat Rev Microbiol       Date:  2019-07-24       Impact factor: 60.633

9.  Immunological Control of Viral Infections in Bats and the Emergence of Viruses Highly Pathogenic to Humans.

Authors:  Tony Schountz; Michelle L Baker; John Butler; Vincent Munster
Journal:  Front Immunol       Date:  2017-09-11       Impact factor: 7.561

10.  Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.

Authors:  Hussein Sweiti; Obinna Ekwunife; Thomas Jaschinski; Stefan K Lhachimi
Journal:  Curr Ther Res Clin Exp       Date:  2017-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.